Welcome to AS 6: Medicine, Drugs and Clinical Trials
Medicines are an essential part of modern healthcare. When you swallow a tablet or receive an injection, how does that medicine travel to where it is needed? How does it actually fix the problem in your cells? And how do scientists know it is safe to use in the first place?
In this chapter of AS Unit 6, we explore the science behind how medicines interact with the human body and how new treatments are tested. Don't worry if medical terms seem unfamiliar at first — we will break down each concept step by step using everyday analogies and easy memory tricks!
To master this topic, we look at two main branches of pharmacology:
• Pharmacokinetics: What the body does to the drug (how the body absorbs, moves, breaks down, and removes the drug).
• Pharmacodynamics: What the drug does to the body (how the drug interacts with cells to produce an effect).
Top Exam Memory Trick:
To remember the difference, look at the letter D:
PharmacoDynamics is what the Drug does to the body!
Part 1: Pharmacokinetics (What the Body Does to the Drug)
Once a medicine enters your body, your body immediately goes to work processing it. This movement and processing is divided into four key stages known as the ADME framework.
The ADME Framework
1. Absorption:
This is the movement of a drug from its site of administration into the bloodstream. For example, when you swallow a pill, it travels down the digestive tract and is absorbed through the stomach or intestinal walls into the blood circulation.
2. Distribution:
Once the drug is in the bloodstream, distribution is the process by which it is reversibly transferred from the blood into various tissues and organs throughout the body where it is needed.
3. Metabolism (Biotransformation):
Metabolism is the chemical alteration of the drug inside the body. The primary organ responsible for metabolism is the liver. The liver uses specialized enzymes to convert the drug into a more water-soluble form, making it easier for the body to eliminate.
4. Excretion:
Excretion is the permanent removal of the drug and its breakdown products from the body. The primary organs responsible for excretion are the kidneys, which filter the drug out of the blood so it can leave the body in urine. Smaller amounts can also be excreted through bile, lungs (breath), or sweat.
Bioavailability
Bioavailability is defined as the fraction of an administered dose of unchanged drug that reaches the systemic (blood) circulation.
• When a drug is given directly into a vein (intravenous injection), none of the drug is lost along the way, meaning it has a bioavailability of \(100\%\).
• When a drug is taken orally as a tablet, some of it might not be fully absorbed or may be broken down before reaching the general circulation, giving it a bioavailability of less than \(100\%\).
Drug Half-Life (\(t_{1/2}\))
The half-life (\(t_{1/2}\)) of a drug is the time taken for the concentration of the drug in the blood plasma to decrease by half (\(50\%\)).
Understanding half-life is vital for doctors and pharmacists because it determines dosage frequency (how often a patient needs to take their medicine to keep it working safely and effectively).
Step-by-Step Half-Life Example:
Suppose a patient is given a dose of a drug, resulting in an initial peak plasma concentration of \(100\text{ mg/L}\). If the drug has a half-life of \(4\text{ hours}\):
• After \(4\text{ hours}\) (1 half-life): the concentration drops to \(50\text{ mg/L}\).
• After \(8\text{ hours}\) (2 half-lives): the concentration drops to \(25\text{ mg/L}\).
• After \(12\text{ hours}\) (3 half-lives): the concentration drops to \(12.5\text{ mg/L}\).
Common Mistake to Avoid:
Half-life is an exponential decay, not a linear reduction. A common error is thinking that if half the drug disappears in \(4\text{ hours}\), all of it will disappear in \(8\text{ hours}\). Remember: in each half-life period, you halve the remaining concentration!
Key Takeaways for Pharmacokinetics
• ADME: Absorption, Distribution, Metabolism (liver), Excretion (kidneys).
• Bioavailability: Fraction of unchanged drug reaching the blood (\(100\%\) for intravenous administration).
• Half-life (\(t_{1/2}\)): Time taken for plasma concentration to halve; sets the dosing schedule.
Part 2: Pharmacodynamics (What the Drug Does to the Body)
Now that the drug has reached the target tissues via the bloodstream, how does it actually exert its effect? This is where Pharmacodynamics comes in.
Receptor Theory
Most drugs work by interacting with specific protein molecules located on the surface or inside of target cells called receptors. You can think of a receptor like a lock, and the chemical that binds to it as a key.
Agonists vs Antagonists
Drugs that bind to receptors generally fall into one of two major categories:
1. Agonist:
An agonist is a drug that binds to a specific receptor and activates it, producing a physiological response. It mimics the body's natural signaling molecules (ligands).
Analogy: An agonist is like the correct key that fits into a lock, turns it, and unlocks the door.
2. Antagonist:
An antagonist is a drug that binds to a receptor but does not activate it. Instead, it sits in the binding site and blocks natural signaling molecules or agonists from binding, thereby preventing or inhibiting a response.
Analogy: An antagonist is like a key that fits into the lock but gets stuck without turning — it prevents any other key from opening the door.
Affinity and Efficacy
Two essential terms describe how well a drug binds and works:
• Affinity: The strength of attraction between a drug and its receptor. A drug with high affinity binds very tightly to its receptor.
• Efficacy: The ability of a drug, once bound, to activate the receptor and produce a biological response.
Putting it together: Both agonists and antagonists can have high affinity (they both bind strongly to the receptor), but only agonists have high efficacy (they actually trigger a biological response).
Key Takeaways for Pharmacodynamics
• Receptors: Specific protein targets on or in cells.
• Agonist: Binds and activates the receptor (produces an effect).
• Antagonist: Binds and blocks the receptor (inhibits an effect).
• Affinity: How well it binds; Efficacy: How well it produces a response.
Part 3: Clinical Trials & Testing New Medicines
Before any new drug can be prescribed to patients, it must undergo rigorous scientific testing to make sure it is safe and works effectively.
The Phases of Drug Development
1. Pre-clinical Testing:
Before a drug is ever given to humans, it is tested in laboratories (using cell and tissue cultures) and on animals. The main goals are to check for basic biological activity and identify any obvious toxicity (harmful or poisonous effects).
2. Phase I Clinical Trials:
• Participants: A small group of \(20\text{--}80\) healthy volunteers.
• Main Focus: Safety, tolerability, establishing safe dosage ranges, and identifying side effects.
• Note: Healthy volunteers are used to see how a healthy human body handles the drug without the confounding factors of an illness.
3. Phase II Clinical Trials:
• Participants: A larger group of \(100\text{--}300\) patients who have the target condition.
• Main Focus: Efficacy (testing if the drug actually works to treat the condition) and monitoring short-term safety.
4. Phase III Clinical Trials:
• Participants: A very large group of \(1{,}000\text{--}3{,}000+\) patients.
• Main Focus: Confirming effectiveness on a wide scale, monitoring for rare side effects, and comparing the new drug against the current standard treatment (standard of care) or a placebo.
5. Phase IV Clinical Trials (Post-Marketing Surveillance):
• Participants: The general population taking the drug after it has been approved and licensed.
• Main Focus: Ongoing monitoring of long-term safety, real-world effectiveness, and very rare adverse effects over many years.
Key Trial Design Standards & Definitions
To ensure trial results are fair, reliable, and free from bias, scientists use specific experimental controls:
• Placebo: An inactive substance (such as a sugar pill or saline injection) that looks identical to the real medicine. It acts as a control to measure the baseline effect of receiving medical attention versus the genuine effect of the drug.
• Double-Blind Trial: A study design where neither the patient nor the researcher/doctor knows who is receiving the active drug and who is receiving the placebo. This prevents psychological expectations (from the patient) and subconscious bias (from the doctor assessing symptoms).
• Randomisation: Assigning participants to the treatment group or control group entirely by chance. This ensures both groups are comparable in terms of age, gender, and health background.
Placebo Ethics — An Important Exam Point
While placebos are important scientific controls, they cannot always be used. If an effective, life-saving treatment already exists for a severe or life-threatening disease, it is unethical to give a patient a placebo (giving them no treatment). In such cases, the new drug is compared directly against the existing standard of care rather than a placebo.
Quick Summary & Exam Checklist
Before your exam, make sure you can confidently answer these core questions:
• Can you list and define the 4 stages of ADME (Absorption, Distribution, Metabolism in the liver, Excretion in the kidneys)?
• Can you explain why intravenous drugs have \(100\%\) bioavailability?
• Can you calculate remaining drug levels using half-life (\(t_{1/2}\))?
• Can you clearly contrast an agonist (activator) with an antagonist (blocker)?
• Do you remember that Phase I is for safety in healthy volunteers, while Phase II is for efficacy in patients?
• Can you explain what a double-blind trial is and why it eliminates bias?